However, there is some evidence that cancer biology is different in BRCA1 carriers compared to non-carriers, with BCRA1 carriers having lower [38] or higher [39] and BRCA2 carriers having higher [40] survival rates, which would result in an over- or under-estimation of the ICER, respectively. This evidence concerns the gene BRCA2 and cancer.